Ori Biotech

Introducing IRO®, the new standard in CGT manufacturing technology. 🎉 Manufacturing remains a critical barrier to scaling cell and gene therapies – making it difficult to meet the patient need, and limiting the clinical and commercial impact of this new class of therapies. That’s why we developed IRO®. IRO® combines an efficient and flexible platform with a scalable, digital solution to industrialize precision medicine manufacturing – delivering a seamless transition from R&D into the clinic, and from clinical scale to commercial scale. By empowering scientists with tools that help accelerate product development and Automate Better Biology, we are working to help enable widespread patient access and scale the impact of life-changing cell and gene therapies. Thank you to everyone who attended our launch at ISCT today. It's an incredibly exciting moment to finally unveil our work over the past 5-years – we are very grateful to the Ori team and our partners for helping us achieve this milestone. Read our full press release: https://lnkd.in/eT3B3MSf Schedule a hands on demo to see how IRO® could work for you: https://lnkd.in/eXEXEGZZ #ISCT2024 #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #Biotechnology

Like nearly 90,000 other people in the US each year, John Bell was told he had lymphoma in fall 2020. John received a diagnosis of large B-cell lymphoma, and received a six month course of traditional chemotherapy. When that was unsuccessful, another treatment offered John new hope...CAR-T therapy. Despite initial side effects, the results of John's CAR-T therapy were nothing short of remarkable. Just one month after treatment, John was symptom-free, full of life, and able to return to his beloved hobbies: "I feel good. It's almost like it never happened" John shares. There is every chance that John may be cured of lymphoma, a hope shared by Dr. Natalie S. Grover at UNC Health, who recommended the therapy. Inspiring stories like John's demonstrate the potential of advanced therapies. As we continue to expand access to cell and gene therapies, we get closer to a future where more patients can benefit from these life-changing treatments. Thank you WILX-TV for sharing John's story ➡️ https://lnkd.in/ekiQwSVC #ManufacturingBrighterFutures #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

CAR-T cell therapy potential continues to grow, but significant development and manufacturing hurdles limit their utilization as treatment options and with that their impact on patient outcomes. While the FDA has approved several CAR-T therapies – with more approvals to come – high costs, more limited number of treatment centers, and long manufacturing turnaround times still risk their widespread use. The momentum of therapy approvals is predicted to accelerate, so it is critical that we tackle these challenges now to ensure widespread patient access to these treatments. IRO®, the new standard in cell and gene therapy manufacturing technology, provides the flexibility and biological performance required to make these products efficiently and cost-effectively at scale. This means that therapies can be not only approvable, but accessible and affordable too. Interested in learning how IRO® can scale your impact? Book a demo today ➡️ https://lnkd.in/eXEXEGZZ Read more: https://lnkd.in/eRtDktDb #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

🔬 Several CAR-T therapies have already received approval as cancer treatments, but researchers believe they’ve found another use: reducing rejections of organ transplants. The Mayo Clinic conducted a proof-of-concept study with 10 patients to evaluate the feasibility of CAR-T cell therapy to improve organ acceptance in patients at risk of rejection. The study, published in Kidney International, used CAR-T cell therapy to target and remove “B cells”, the cells that trigger immune reactions against donor organs. While in its early stages – just 9 kidney and 1 lung transplant patients have been involved so far – the authors believe the technique could lead to an increase in success rates, and reduce the time patients spend on the organ transplant list. Based on this proof of concept, the Mayo Clinic is preparing to manufacture these CAR-T cells for early-stage clinical trials. Read more: https://lnkd.in/eMuX8uqQ #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

🧬 Advanced therapies could transform patient outcomes – but improving access requires us to overcome the barriers to scaling in CGT manufacturing. Jason C. Foster, Ori Biotech’s CEO, recently spoke to Anshul Mangal, President at Project Farma (PF), about the critical importance of process, throughput, failure rates, and cost in the CGT manufacturing. Until these are solved, we will continue to see challenges to viability of our industry. We are committed to empowering scientists with flexible tools that streamline development to scale the impact of life-changing therapies. Our IRO® platform aims to address these barriers to viability directly: by automating and scaling CGT manufacturing, increasing efficiency, and reducing the costs of therapy development. This ensures that advanced therapies are not only widely available to patients but affordable, too. Listen to Anshul's episode of the Ori Spotlight Podcast: 🎧 Spotify: https://lnkd.in/efD6iM79 📺 Youtube: https://lnkd.in/eWtHtexx #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

Experience IRO® – the new standard of CGT manufacturing... 📆 Join Jason C. Foster, Ori Biotech CEO and Matthew Hewitt Vice President, CTO Manufacturing at Charles River Laboratories in Boston MA on Sept 17, and say hello to IRO in person! Don’t miss out on: 🔹 New platform data 🔹 In-person IRO demos 🔹 Refreshments and networking Stay tuned for more details and sign up now to secure your place ➡️ https://lnkd.in/euYDCCvD #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

In January 2021, Bill Hoffman discovered two small lumps on his neck. Diagnosed with melanoma, he underwent surgery and immunotherapy but his cancer continued to progress, spreading to his lymph nodes. When he ran out of options, Bill turned to Moffitt Cancer Center, where he learned about the tumor-infiltrating lymphocyte (TIL) therapy, lifileucel and became Moffitt’s first commercial TIL therapy patient. On March 26, 2024, Bill underwent a tumor harvest, before receiving the lifileucel infusion on May 16. He is now waiting to find out if the treatment has been successful. “TIL therapy is the most reliable option after traditional standard-of-care therapies have failed”, said the center’s Dr. Amod Sarnaik. More trials are being conducted to find ways to reduce the manufacturing time and create a better product with a higher success rate. Treatments like lifileucel offer hope for patients with aggressive cancers. Ensuring these therapies are approvable, accessible and affordable is essential to providing life-saving options to more patients in need. Thank you Moffitt Cancer Center for sharing Bill’s inspiring story. https://lnkd.in/eEZvvmj6 #ManufacturingBrighterFutures #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

🔬 FDA has approved Breyanzi®, a CAR-T therapy for treating adult patients with relapsed or refractory mantle cell lymphoma. This marks the fourth distinct subtype of non-Hodgkin lymphoma that Bristol Myers Squibb’s Breyanzi® can treat, making it the broadest CAR-T cell therapy available for B-cell malignancies. Responses were observed in 85.3% of patients with a one-time infusion while maintaining a consistent safety profile in clinical trials. This highlights the potential of Breyanzi® to offer long-lasting responses for patients with few treatment alternatives. With the rising number of CAR-T therapy approvals, it's vital that these treatments are accessible and affordable for everyone, ensuring widespread patient access to these life-changing therapies. Book a demo to learn how IRO® can help scale the production and delivery of advanced therapies ➡️ https://lnkd.in/eXEXEGZZ Read more: https://lnkd.in/eMq-Vp8j #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

🔬Early trials of CAR-T therapy for prostate cancer have seen promising results. New data published by City of Hope from a Phase 1 clinical trial of prostate stem cell antigen (PSCA)-CAR-T cell therapy in metastatic castration-resistant prostate cancer (mCRPC) shows durable remissions in hematological malignancies. This first-in-human study evaluates the safety and bioactivity of PSCA-directed CAR-T cells in men with mCRPC. Early findings indicate a significant decline in prostate-specific antigens and radiographic improvements, demonstrating the potential of CAR-T therapies to transform treatment for solid tumors like prostate cancer. As the momentum of CAR-T cell therapy approvals increases, the industry must work together to scale manufacturing of these therapies and ensure they are accessible and affordable for all patients. Accelerating product development and leveraging digital manufacturing solutions will be key to making life-changing therapies more widely available. Read more in Nature: https://lnkd.in/gSJ7TmRz #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

🧬 Automating the digital systems use in therapy development will bring treatments to a wider group of patients. Anshul Mangal, President at Project Farma (PF) joined Ori Biotech’s Jason C. Foster on the Ori Spotlight Podcast to discuss the automated, digital systems required to efficiently scale CGT manufacturing so that more patients can benefit. Without these advancements, high costs and time requirements to scale facilities for larger patient populations could hinder access to life-changing therapies. IRO®'s ability to increase throughput from a smaller footprint means we can reduce manufacturing costs and improve patient access, making these therapies more accessible to those in need. Ultimately, embracing technologies like IRO® help us Automate Better Biology™ and scale the impact of life-changing therapies. 🎧 Listen on Spotify: https://lnkd.in/efD6iM79 📺 Watch on Youtube: https://lnkd.in/eWtHtexx #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact